JOHNSON CITY, Tenn., Feb. 3, 2025 /PRNewswire/ -- LabConnect, a leading provider of central lab services and functional ...

JOHNSON CITY, Tenn., Feb. 3, 2025 /PRNewswire/ -- LabConnect, a leading provider of central lab services and functional service provider solutions, is proud to announce the formation of its ...

JOHNSON CITY, Tenn., Feb. 4, 2025 /PRNewswire/ — LabConnect, a leading provider of central lab services and functional service provider solutions, is proud to announce the formation of its Strategic ...

Bearish flow noted in Merck (MRK) with 177,294 puts trading, or 7x expected. Most active are Feb-25 98 puts and Feb-25 100 puts, with total ...

TD Cowen downgraded Merck (MRK) to Hold from Buy with a price target of $100, down from $121. The firm says its Buy thesis “broke down” with ...

Pause on Gardasil China sales from Feb to at least mid-2025 Keytruda beats, Gardasil misses Q4 sales estimates Merck pulls Gardasil's long-term sales target Shares tumble 11% in early trading Feb ...

Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed fourth-quarter earnings. Its full-year revenue and EPS guidance missed by ...

Merck reported Q4 sales of $15.62 billion, up 7% YoY, exceeding the $15.49 billion estimate. Goldman Sachs raises Merck's price target to $135, citing growth potential. NOW OPEN: 200 Charter ...

Merck’s Q4 sales rose 7% YoY to $15.62B, slightly beating the $15.49B consensus. Adjusted EPS jumped to $1.72, topping estimates of $1.62. Keytruda sales grew 19% YoY to $7.84B, while Gardasil ...

For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion.

Investing.com -- Merck &Company Inc (NYSE:MRK) shares tumbled more than 10% Tuesday after reporting mixed fourth-quarter results, with earnings falling short of expectations, revenue surpassing ...

On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...